Acrivon Therapeutics, Inc. Common Stock
ACRVAcrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company's platform combines genomics, proteomics, and machine learning to identify targeted therapies and biomarkers, aiming to improve patient outcomes in various oncology indications.
Company News
Acrivon Therapeutics announced preclinical data showing strong synergies between its lead assets ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) when combined with anti-PD-L1 checkpoint inhibitors and ADC payloads. The company will present three posters at the AACR 2026 Annual Meeting in San Diego, demonstrating potent efficacy an...
Acrivon Therapeutics announced three poster presentations at the 2026 AACR Annual Meeting showcasing preclinical data demonstrating strong synergy of ACR-368 (CHK1/2 inhibitor) with Topoisomerase 1 inhibitor ADC payloads, and synergy of both ACR-368 and ACR-2316 (WEE1/PKMYT1 inhibitor) with immune checkpoint inhibitors. The data highlight the com...
A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.
Acrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.
Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.
